Retraction notice to “Notch-1 induces Epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells” (Cancer Letters (2011) 307(1) (26–36), (S0304383511001625), (10.1016/j.canlet.2011.03.012));Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells

Cancer Letters

Volumn 307, Issue 1, 2011, Pages 26-36

  Bao, Bin ^a   Wang, Zhiwei ^a   Ali, Shadan ^b   Kong, Dejuan ^a   Li, Yiwei ^a   Ahmad, Aamir ^a   Banerjee, Sanjeev ^a   Azmi, Asfar S ^a   Miele, Lucio ^c   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

CSC self renewal; EMT phenotype; Genistein; MiRNAs; Notch 1

Indexed keywords

BETA ACTIN; CYCLIN D1; EPITHELIAL CELL ADHESION MOLECULE; GENISTEIN; HERMES ANTIGEN; NOTCH1 RECEPTOR; ONCOPROTEIN; PROTEIN ZEB1; PROTEIN ZEB2; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VIMENTIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL GROWTH; CELL MIGRATION; CELL RENEWAL; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MORPHOLOGY; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; WOUND HEALING;

EID: 79957487931     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2018.03.020     Document Type: Erratum

References (50)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
2. Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A., Schrag D., Jamison P.M., Jemal A., Wu X.C., Friedman C., Harlan L., Warren J., Anderson R.N., Pickle L.W. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J. Natl. Cancer Inst. 2005, 97:1407-1427.
3. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
4. Arslan A.A., Helzlsouer K.J., Kooperberg C., Shu X.O., Steplowski E., Bueno-de-Mesquita H.B., Fuchs C.S., Gross M.D., Jacobs E.J., Lacroix A.Z., Petersen G.M., Stolzenberg-Solomon R.Z., Zheng W., Albanes D., Amundadottir L., Bamlet W.R., Barricarte A., Bingham S.A., Boeing H., Boutron-Ruault M.C., Buring J.E., Chanock S.J., Clipp S., Gaziano J.M., Giovannucci E.L., Hankinson S.E., Hartge P., Hoover R.N., Hunter D.J., Hutchinson A., Jacobs K.B., Kraft P., Lynch S.M., Manjer J., Manson J.E., McTiernan A., McWilliams R.R., Mendelsohn J.B., Michaud D.S., Palli D., Rohan T.E., Slimani N., Thomas G., Tjonneland A., Tobias G.S., Trichopoulos D., Virtamo J., Wolpin B.M., Yu K., Zeleniuch-Jacquotte A., Patel A.V. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch. Int. Med. 2010, 170:791-802.
5. Wang Z., Li Y., Banerjee S., Sarkar F.H. Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res. 2008, 28:3621-3630.
6. Miele L. Notch signaling. Clin. Cancer Res. 2006, 12:1074-1079.
7. Miele L., Miao H., Nickoloff B.J. NOTCH signaling as a novel cancer therapeutic target. Curr. Cancer Drug Targets 2006, 6:313-323.
8. Okuyama R., Tagami H., Aiba S. Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases. J. Dermatol. Sci. 2008, 49:187-194.
9. Miele L., Osborne B. Arbiter of differentiation and death: notch signaling meets apoptosis. J. Cell. Physiol. 1999, 181:393-409.
10. Shou J., Ross S., Koeppen H., de Sauvage F.J., Gao W.Q. Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res. 2001, 61:7291-7297.
11. Sriuranpong V., Borges M.W., Ravi R.K., Arnold D.R., Nelkin B.D., Baylin S.B., Ball D.W. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res. 2001, 61:3200-3205.
12. Miyamoto Y., Maitra A., Ghosh B., Zechner U., Argani P., Iacobuzio-Donahue C.A., Sriuranpong V., Iso T., Meszoely I.M., Wolfe M.S., Hruban R.H., Ball D.W., Schmid R.M., Leach S.D. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003, 3:565-576.
13. Bolos V., Grego-Bessa J., de la Pompa J.L. Notch signaling in development and cancer. Endocr. Rev. 2007, 28:339-363.
14. Aster J.C., Pear W.S., Blacklow S.C. Notch signaling in leukemia. Annu. Rev. Pathol. 2008, 3:587-613.
15. Reedijk M., Odorcic S., Chang L., Zhang H., Miller N., McCready D.R., Lockwood G., Egan S.E. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005, 65:8530-8537.
16. Wang Z., Li Y., Ahmad A., Azmi A.S., Banerjee S., Kong D., Sarkar F.H. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim. Biophys. Acta 2010, 1806:258-267.
17. Grudzien P., Lo S., Albain K.S., Robinson P., Rajan P., Strack P.R., Golde T.E., Miele L., Foreman K.E. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res. 2010, 30:3853-3867.
18. Sarkar F.H., Li Y., Wang Z., Kong D. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir. 2009, 64:489-500.
19. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
20. Wang Z., Li Y., Kong D., Sarkar F.H. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr. Drug Targets 2010, 11:745-751.
21. Ali S., Ahmad A., Banerjee S., Padhye S., Dominiak K., Schaffert J.M., Wang Z., Philip P.A., Sarkar F.H. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010, 70:3606-3617.
22. Kong D., Li Y., Wang Z., Banerjee S., Ahmad A., Kim H.R., Sarkar F.H. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009, 27:1712-1721.
23. Kong D., Banerjee S., Ahmad A., Li Y., Wang Z., Sethi S., Sarkar F.H. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010, 5:e12445.
24. Mahato R., Qin B., Cheng K. Blocking IKKalpha expression inhibits prostate cancer invasiveness. Pharm. Res. 2010.
25. Kong D., Wang Z., Sarkar S.H., Li Y., Banerjee S., Saliganan A., Kim H.R., Cher M.L., Sarkar F.H. Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 2008, 26:1425-1435.
26. Kong D., Li Y., Wang Z., Banerjee S., Sarkar F.H. Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res. 2007, 67:3310-3319.
27. Li Y., VandenBoom T.G., Kong D., Wang Z., Ali S., Philip P.A., Sarkar F.H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69:6704-6712.
28. Desmouliere A. Factors influencing myofibroblast differentiation during wound healing and fibrosis. Cell Biol. Int. 1995, 19:471-476.
29. Peter M.E. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 2009, 8:843-852.
30. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 2008, 14:818-829.
31. Pannuti A., Foreman K., Rizzo P., Osipo C., Golde T., Osborne B., Miele L. Targeting Notch to target cancer stem cells. Clin. Cancer Res. 2010, 16:3141-3152.
32. Sethi S., Macoska J., Chen W., Sarkar F.H. Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am. J. Transl. Res. 2010, 3:90-99.
33. Billottet C., Tuefferd M., Gentien D., Rapinat A., Thiery J.P., Broet P., Jouanneau J. Modulation of several waves of gene expression during FGF-1 induced epithelial-mesenchymal transition of carcinoma cells. J. Cell Biochem. 2008, 104:826-839.
34. Wang Z., Li Y., Banerjee S., Sarkar F.H. Emerging role of Notch in stem cells and cancer. Cancer Lett. 2009, 279:8-12.
35. Garzon R., Fabbri M., Cimmino A., Calin G.A., Croce C.M. MicroRNA expression and function in cancer. Trends Mol. Med. 2006, 12:580-587.
36. DeSano J.T., Xu L. MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J. 2009, 11:682-692.
37. Perera R.J., Ray A. MicroRNAs in the search for understanding human diseases. BioDrugs 2007, 21:97-104.
38. Park S.M., Gaur A.B., Lengyel E., Peter M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22:894-907.
39. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
40. Mikels A.J., Nusse R. Wnts as ligands: processing, secretion and reception. Oncogene 2006, 25:7461-7468.
41. Ischenko I., Seeliger H., Kleespies A., Angele M.K., Eichhorn M.E., Jauch K.W., Bruns C.J. Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks Arch. Surg. 2010, 395:1-10.
42. Phillips T.M., Kim K., Vlashi E., McBride W.H., Pajonk F. Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia 2007, 9:1122-1129.
43. Wang Z., Zhang Y., Li Y., Banerjee S., Liao J., Sarkar F.H. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol. Cancer Ther. 2006, 5:483-493.
44. Wang Z., Kong D., Banerjee S., Li Y., Adsay N.V., Abbruzzese J., Sarkar F.H. Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res. 2007, 67:11377-11385.
45. Schreck K.C., Taylor P., Marchionni L., Gopalakrishnan V., Bar E.E., Gaiano N., Eberhart C.G. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin. Cancer Res. 2010, 16:6060-6070.
46. Slusarz A., Shenouda N.S., Sakla M.S., Drenkhahn S.K., Narula A.S., MacDonald R.S., Besch-Williford C.L., Lubahn D.B. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res. 2010, 70:3382-3390.
47. Wang Z., Zhang Y., Banerjee S., Li Y., Sarkar F.H. Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int. J. Cancer 2006, 118:1930-1936.
48. Wang Z., Li Y., Kong D., Ahmad A., Banerjee S., Sarkar F.H. Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett. 2010, 292:141-148.
49. Wang Z., Li Y., Ahmad A., Banerjee S., Azmi A.S., Kong D., Wojewoda C., Miele L., Sarkar F.H. Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J. Cell Biochem. 2010.
50. Takebe N., Harris P.J., Warren R.Q., Ivy S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 2010.